Shaolin Capital Management’s Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 CLDI.WS Stock Holding History

Shaolin Capital Management’s Portfolio CLDI.WS Stock Details CLDI.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-330,547	Closed	-$4.33K	–	324
2024 Q3	$4.33K	Sell	330,547 -119,453	-27%	-$3.65K	﹤0.01%	247
2024 Q2	$18.9K	Hold	450,000	–	–	﹤0.01%	244
2024 Q1	$23.4K	Hold	450,000	–	–	﹤0.01%	222
2023 Q4	$22.5K	Sell	450,000 -200,000	-31%	-$22.7K	﹤0.01%	279
2023 Q3	$143K	Buy	+650,000	New	+$119K	0.01%	246
2023 Q2	–	Sell	-600,000	Closed	-$48.5K	–	807
2023 Q1	$25K	Buy	600,000 +104,362	+21%	+$8.1K	﹤0.01%	530
2022 Q4	$25K	Hold	495,638	–	–	﹤0.01%	550
2022 Q3	$28K	Hold	495,638	–	–	﹤0.01%	665
2022 Q2	$45K	Sell	495,638 -2,200	-0.4%	-$488	﹤0.01%	705
2022 Q1	$179K	Buy	+497,838	New	+$219K	﹤0.01%	584

Other funds holding CLDI.WS

EAM

Exos Asset Management New York $2.32K AUM 108.13% 1-Year Est. Return

Shaolin Capital Management's CLDI.WS Position: Q4 2024 in Review

Shaolin Capital Management sold out of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) in Q4 2024, closing a stake of 330,547 shares — an estimated $4.33K sold.

Shaolin Capital Management first reported a position in CLDI.WS in Q1 2022 and held it in 10 quarters. The position peaked at $179K in Q1 2022. 1 fund tracked by Wall St. Rank holds CLDI.WS as of Q4 2024.

Shaolin Capital Management reported no remaining Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position as of Q4 2024 after selling out during the quarter.
Shaolin Capital Management sold 330,547 Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 shares in Q4 2024, an estimated $4.33K.
Shaolin Capital Management first reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in Q1 2022 and held it in 10 quarters.
Shaolin Capital Management's Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position peaked at $179K in Q1 2022.
1 fund tracked by Wall St. Rank held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 as of Q4 2024.

Based on Shaolin Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.